About Secretome Therapeutics
Secretome Therapeutics is a company based in Dallas (United States) founded in 2018 by Sunjay Kaushal. Secretome Therapeutics has raised $22.15 million across 3 funding rounds from investors including Parent Project Muscular Dystrophy. Secretome Therapeutics offers products and services including STM-01 and STM-21. Secretome Therapeutics operates in a competitive market with competitors including AskBio, Calliditas Therapeutics, Inotrem, Enyo Pharma and Mesoblast, among others.
- Headquarter Dallas, United States
- Founders Sunjay Kaushal
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Secretome Therapeutics, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$22.15 M (USD)
in 3 rounds
-
Latest Funding Round
$250 K (USD), Series B
Mar 24, 2026
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Secretome Therapeutics
Secretome Therapeutics offers a comprehensive portfolio of products and services, including STM-01 and STM-21.
Drug derived from nCPCs for treating heart failure and related conditions.
Secretome from nCPCs aimed at regenerative cardiovascular therapies.
People of Secretome Therapeutics
Unlock access to complete
Unlock access to complete
Scientific Team
5 people
Leadership Team
4 people
Operations Team
2 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of Secretome Therapeutics
Secretome Therapeutics has successfully raised a total of $22.15M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $250 thousand completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Secretome Therapeutics
Secretome Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Parent Project Muscular Dystrophy.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Secretome Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Secretome Therapeutics
Investment portfolio details for Secretome Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Secretome Therapeutics
Detailed financials for Secretome Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Secretome Therapeutics Comparisons
Peer comparison for Secretome Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Secretome Therapeutics
Secretome Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AskBio, Calliditas Therapeutics, Inotrem, Enyo Pharma and Mesoblast, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| Locked | Locked | Locked |
Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction
|
|
| Locked | Locked | Locked |
Therapeutics are developed for diseases with impaired kidney function.
|
|
| Locked | Locked | Locked |
Biotherapeutics derived from proprietary adult stem cell-based technologies
|
|
| Locked | Locked | Locked |
Small molecule therapies for kidney diseases are developed.
|
Detailed competitors of Secretome Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Secretome Therapeutics
Complete news archive for Secretome Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Secretome Therapeutics
Secretome Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Secretome Therapeutics is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
Vinny Jindal is the current CEO of Secretome Therapeutics.
Secretome Therapeutics is a funded company, having raised a total of $22.15M across 3 funding rounds to date.
Secretome Therapeutics was founded in 2018 in Dallas, United States, within the biotechnology sector. Cell-based therapies targeting various diseases are developed, with operations focused on innovative treatments. Lead products include STM-21, designed to prevent inflammatory toxicities from cancer therapies like cisplatin-induced acute kidney injury, and STM-01, a therapy using neonatal mesenchymal stem cells to restore cardiac function following heart attacks.
Secretome Therapeutics's top competitors include Juvenescence, AskBio and Mission Therapeutics.
Secretome Therapeutics offers STM-01 and STM-21.
Secretome Therapeutics has 1 investor. Key investors include Parent Project Muscular Dystrophy.